PurposeTo provide a comprehensive overview of the current main applications of long axial field-of-view (LAFOV) PET/CT in oncology.MethodsRelevant studies published from 2017 up to September 2022 were selected by searching Scopus, PubMed, and Web of Science. The following data were extracted: characteristics of studies and patients, technical aspects, and usefulness of the LAFOV PET/CT in the oncological setting. Selected imaging studies were analyzed using a modified version of the Critical Appraisal Skills Programme (CASP).ResultsSeventeen papers were finally selected: 12 (70.6%) were retrospective, while 5 (29.4%) were prospective, with an overall number of 877 included patients. Most of the studies (14/17, 82.4%) employed [F-18]-FDG as a radiopharmaceutical agent, 2 papers used [Ga-68]-PSMA-11 and 1 employed mixed tracers. Eleven studies were focused on protocols at low/ultra-low activity or with fast/ultra-fast scanning time, 3 papers compared the performance of LAFOV PET/CT scanners with that of conventional (standard axial field-of-view/SAFOV) devices, 4 were total-body PET dynamic studies.ConclusionsLAFOV PET/CT showed superior diagnostic performance than traditional SAFOV devices, allowing reduced activity/time and dynamic protocols. The applications of this novel technology in some clinical settings, mainly the pediatric population, are promising but should be a topic of future investigations.

Clinical applications of long axial field-of-view PET/CT scanners in oncology

Urso L.
Primo
;
2023

Abstract

PurposeTo provide a comprehensive overview of the current main applications of long axial field-of-view (LAFOV) PET/CT in oncology.MethodsRelevant studies published from 2017 up to September 2022 were selected by searching Scopus, PubMed, and Web of Science. The following data were extracted: characteristics of studies and patients, technical aspects, and usefulness of the LAFOV PET/CT in the oncological setting. Selected imaging studies were analyzed using a modified version of the Critical Appraisal Skills Programme (CASP).ResultsSeventeen papers were finally selected: 12 (70.6%) were retrospective, while 5 (29.4%) were prospective, with an overall number of 877 included patients. Most of the studies (14/17, 82.4%) employed [F-18]-FDG as a radiopharmaceutical agent, 2 papers used [Ga-68]-PSMA-11 and 1 employed mixed tracers. Eleven studies were focused on protocols at low/ultra-low activity or with fast/ultra-fast scanning time, 3 papers compared the performance of LAFOV PET/CT scanners with that of conventional (standard axial field-of-view/SAFOV) devices, 4 were total-body PET dynamic studies.ConclusionsLAFOV PET/CT showed superior diagnostic performance than traditional SAFOV devices, allowing reduced activity/time and dynamic protocols. The applications of this novel technology in some clinical settings, mainly the pediatric population, are promising but should be a topic of future investigations.
2023
Urso, L.; Frantellizzi, V.; De Vincentis, G.; Schillaci, O.; Filippi, L.; Evangelista, L.
File in questo prodotto:
File Dimensione Formato  
s40336-023-00547-7 (1).pdf

solo gestori archivio

Descrizione: Full text ahead of print
Tipologia: Full text (versione editoriale)
Licenza: Copyright dell'editore
Dimensione 713.38 kB
Formato Adobe PDF
713.38 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
s40336-023-00547-7.pdf

solo gestori archivio

Descrizione: Full text editoriale
Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 695.15 kB
Formato Adobe PDF
695.15 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2509511
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 12
social impact